SCHEDULE: Capitalink Discloses 9.99% Stake in Clearmind Medicine
Beneficial Ownership Report (Schedule 13G)
Capitalink Ltd. has reported a 9.99% beneficial ownership stake in Clearmind Medicine Inc., as detailed in a recent Schedule 13G filing.
Summary
- Capitalink Ltd., an entity based in Israel, has filed a Schedule 13G indicating beneficial ownership of common shares in Clearmind Medicine Inc.
- The reporting person, Capitalink Ltd., beneficially owns 3,307,291 common shares of Clearmind Medicine Inc.
- This ownership represents 9.99% of Clearmind Medicine Inc.'s outstanding common shares.
- The percentage is calculated based on 33,106,024 common shares issued and outstanding, as reported by Clearmind Medicine Inc. in a prospectus supplement filed on November 19, 2025.
- Capitalink Ltd. holds sole voting power and sole dispositive power over all 3,307,291 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive. A significant stake (9.99%) by an institutional investor, even if passive, can be viewed favorably by the market as it indicates confidence in the company. The certification of passive intent mitigates concerns about potential activist intervention.
Positives
- A significant institutional investor, Capitalink Ltd., has taken a substantial 9.99% stake in Clearmind Medicine Inc., which could be interpreted as a vote of confidence in the company's prospects.
Risks
- While the filing certifies a passive investment intent, any large ownership stake introduces the potential for future influence or changes in investment strategy by the holder, which could impact the company.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Clearmind Medicine Inc.'s future performance or strategic direction.
Management Comments
- Lavi Krasney, Chief Executive Officer of Capitalink Ltd., certified that, to the best of his knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing is a standard disclosure of a significant ownership stake by an institutional investor and does not provide broader industry trend analysis or competitive insights.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor taking a near-10% stake could be perceived as a positive signal, potentially increasing investor confidence and demand for the stock.
Key Dates
| Date | Description |
|---|---|
| 11/19/2025 | Date of event which requires the filing of this statement, and the date Clearmind Medicine Inc. reported 33,106,024 common shares outstanding in a prospectus supplement. |
| 12/01/2025 | Date the Schedule 13G statement was signed by Capitalink Ltd. |
Keywords
Clearmind Medicine Inc., Capitalink Ltd., Schedule 13G, Beneficial Ownership, Common Shares, Equity Stake, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.